Search Result

Results for "

OPC

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (16) Adrenergic Receptor (10) Antibiotic (5) Autophagy (5) Bacterial (8) Bcl-2 Family (1) Calcium Channel (1) Caspase (1) COX (3) CXCR (1) Dopamine Receptor (9) Drug Metabolite (3) Elastase (1) Isotope-Labeled Compounds (8) MEK (1) Mitochondrial Metabolism (1) Opioid Receptor (1) Phosphatase (1) Phosphodiesterase (PDE) (8) Phospholipase (1) Prostaglandin Receptor (1) Reactive Oxygen Species (1) Sigma Receptor (2) Vasopressin Receptor (6)
By Research Areas:	Cancer (17) Cardiovascular Disease (18) Endocrinology (10) Infection (13) Inflammation/Immunology (12) Metabolic Disease (5) Neurological Disease (20)

By Targets:

5-HT Receptor (16)

Adrenergic Receptor (10)

Antibiotic (5)

Autophagy (5)

Bacterial (8)

Bcl-2 Family (1)

Calcium Channel (1)

Caspase (1)

COX (3)

CXCR (1)

Dopamine Receptor (9)

Drug Metabolite (3)

Elastase (1)

Isotope-Labeled Compounds (8)

MEK (1)

Mitochondrial Metabolism (1)

Opioid Receptor (1)

Phosphatase (1)

Phosphodiesterase (PDE) (8)

Phospholipase (1)

Prostaglandin Receptor (1)

Reactive Oxygen Species (1)

Sigma Receptor (2)

Vasopressin Receptor (6)

By Research Areas:

Cancer (17)

Cardiovascular Disease (18)

Endocrinology (10)

Infection (13)

Inflammation/Immunology (12)

Metabolic Disease (5)

Neurological Disease (20)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-134769

OPC-163493	Mitochondrial Metabolism Reactive Oxygen Species	Cardiovascular Disease Metabolic Disease
OPC-163493 is an orally active liver-targeted mitochondrial uncoupling agent. OPC-163493 reduces Δψ and mitochondrial ROS production. OPC-163493 has antidiabetic and cardiovascular beneficial effects. OPC-163493 lowers blood pressure, extends survival, and improves renal function in the rat model of stroke/hypertension .

HY-17495A

Carteolol hydrochloride 2 Publications Verification OPC-1085 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Carteolol hydrochloride (OPC-1085 hydrochloride) is a non-selective beta blocker used to treat glaucoma.

HY-106781A

OPC 4392 hydrochloride	Dopamine Receptor	Neurological Disease
OPC 4392 hydrochloride is an agonist for presynaptic dopamine receptor and an antagonist for postsynaptic D2 receptor. OPC 4392 reverses the Reserpine (HY-N0480)-induced dopamine accumulation, inhibits Apomorphine (HY-12723)-induced stereotypic and climbing behaviors in mouse models .

HY-116594A

OPC-14523 hydrochloride	Sigma Receptor 5-HT Receptor	Neurological Disease
OPC-14523 hydrochloride is an orally active sigma and 5-HT1A receptor agonist, with high affinity for sigma receptors (σ1/2 IC₅₀=47/56 nM), the 5-HT1A receptor (IC₅₀=2.3 nM), and the 5-HT transporter (IC₅₀=80 nM). OPC-14523 hydrochloride shows antidepressant-like activity .

HY-15009

Fuscoside 1 Publications Verification OPC-21268	Vasopressin Receptor	Cardiovascular Disease Endocrinology
Fuscoside (OPC-21268) is an orally effective, nonpeptide, vasopressin V1 receptor antagonist with an IC₅₀ of 0.4 μM.

HY-19664

Pranidipine OPC-13340	Calcium Channel	Cardiovascular Disease
Pranidipine (OPC-13340) is a potent, long acting 1,4-dihydropyridine calcium channel blocker with antihypertensive activity .

HY-116567

OPC-51803	Vasopressin Receptor	Metabolic Disease
OPC-51803 is an orally active nonpeptide vasopressin V₂ receptor agonist. OPC-51803 can be used for the research of micturition disorders that result in frequent micturition, such as that from polyuria, nocturnal polyuria, and some kinds of urinary incontinence .

HY-167079A

OPC-18750 hydrochloride	Others	Cardiovascular Disease
OPC-18750 hydrochloride has positive inotropic and coronary vasodilatory effects .

HY-105092

Tetomilast OPC-6535	Phosphodiesterase (PDE)	Inflammation/Immunology
Tetomilast (OPC-6535) is a PDE4 inhibitor with potential for the research of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD).

HY-101610

OPC-28326	Adrenergic Receptor	Cardiovascular Disease Endocrinology
OPC-28326 is a selective peripheral vasodilator and an angatonist of α2-adrenergic receptor, with K_i of 2040, 285, and 55?nM for α2A-, α2B- and α2C-adrenoceptors, respectively.

HY-134940

Quabodepistat OPC-167832	Bacterial	Infection Inflammation/Immunology
Quabodepistat (OPC-167832) is a potent and orally active dprE1 inhibitor with an IC₅₀ of 0.258 μM. Quabodepistat has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis .

HY-116594

OPC-14523 free base	Sigma Receptor 5-HT Receptor	Neurological Disease
OPC-14523 free base is an orally active sigma and 5-HT1A receptor agonist, with high affinity for sigma receptors (σ1/2 IC₅₀=47/56 nM), the 5-HT1A receptor (IC₅₀=2.3 nM), and the 5-HT transporter (IC₅₀=80 nM). OPC-14523 free base shows antidepressant-like activity .

HY-17464

Cilostazol 3 Publications Verification OPC 13013	Phosphodiesterase (PDE) Autophagy	Cardiovascular Disease Cancer
Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM .

HY-15297

Vesnarinone 1 Publications Verification OPC-8212	Phosphodiesterase (PDE)	Infection Cardiovascular Disease
Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research .

HY-B0506

Nadifloxacin 1 Publications Verification OPC7251	Bacterial Antibiotic	Infection
Nadifloxacin (OPC7251) is a broad-spectrum fluoroquinolone antibiotic that is effective against acne vulgaris.

HY-A0147

Grepafloxacin OPC-17116; dl-Grepafloxacin	Antibiotic Bacterial	Infection
Grepafloxacin (OPC-17116) is an oral actively fluoroquinolone antibiotic with potent activity against community-acquired respiratory pathogens including Streptococcus pneumonia. Grepafloxacin has high tissue penetration and a promising pharmacodynamic profile .

HY-135910

3,4-Dehydro Cilostazol OPC-13015	Drug Metabolite	Cardiovascular Disease Cancer
3,4-Dehydro Cilostazol (OPC-13015) is an active metabolite of Cilostazol (CLZ; HY-17464). 3,4-Dehydro Cilostazol is used for pharmacokinetic study .

HY-100665

Dehydroaripiprazole 1 Publications Verification OPC-14857; DM-14857	5-HT Receptor	Neurological Disease
Dehydroaripiprazole (OPC-14857) is an active metabolite of Aripiprazole. Aripiprazole is an antipsychotic agent and is metabolized by CYP3A4 and CYP2D6 forming mainly Dehydroaripiprazole. Dehydroaripiprazole has with antipsychotic activity equivalent to Aripiprazole .

HY-A0147A

Grepafloxacin hydrochloride OPC-17116 hydrochloride; dl-Grepafloxacin hydrochloride	Antibiotic Bacterial	Infection
Grepafloxacin (OPC-17116) hydrochloride is an oral actively fluoroquinolone antibiotic with potent activity against community-acquired respiratory pathogens including Streptococcus pneumonia. Grepafloxacin hydrochloride has high tissue penetration and a promising pharmacodynamic profile .

HY-113575

Dehydroaripiprazole hydrochloride OPC-14857 hydrochloride; DM-14857 hydrochloride	5-HT Receptor	Neurological Disease
Dehydroaripiprazole (OPC-14857) hydrochloride is an active metabolite of Aripiprazole. Aripiprazole is an antipsychotic agent and is metabolized by CYP3A4 and CYP2D6 forming mainly Dehydroaripiprazole hydrochloride. Dehydroaripiprazole hydrochloride has with antipsychotic activity equivalent to Aripiprazole .

HY-17495AS

Carteolol-d9 hydrochloride OPC-1085-d₉ hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease Endocrinology
Carteolol-d₉ (hydrochloride) is the deuterium labeled Carteolol hydrochloride. Carteolol hydrochloride (OPC-1085 hydrochloride) is a non-selective beta blocker used to treat glaucoma[1][2].

HY-18346

Mozavaptan 1 Publications Verification OPC-31260	Vasopressin Receptor	Metabolic Disease Endocrinology Cancer
Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V₂ receptor antagonist with an IC₅₀ of 14 nM. Mozavaptan shows ~85-fold selectivity for V₂ receptor over V₁ receptor (IC₅₀ of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .

HY-123593

Mozavaptan hydrochloride 1 Publications Verification OPC-31260 hydrochloride	Vasopressin Receptor	Metabolic Disease Endocrinology Cancer
Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V₂ receptor antagonist with an IC₅₀ of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V₂ receptor over V₁ receptor (IC₅₀ of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .

HY-14546

Aripiprazole 5+ Cited Publications OPC-14597	5-HT Receptor Dopamine Receptor	Infection Neurological Disease Inflammation/Immunology
Aripiprazole (OPC-14597), an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole can be used for the research of schizophrenia and COVID19 .

HY-15780

Brexpiprazole 3 Publications Verification OPC-34712	5-HT Receptor Dopamine Receptor Adrenergic Receptor	Neurological Disease
Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D_2L receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a K_i of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α_1B (K_i=0.17 nM) and α_2C receptors (K_i=0.59 nM) .

HY-14546A

Aripiprazole monohydrate OPC-14597 monohydrate	5-HT Receptor Dopamine Receptor	Infection Neurological Disease Inflammation/Immunology
Aripiprazole (OPC-14597) monohydrate, an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole monohydrate is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole monohydrate can be used for the research of schizophrenia and COVID19 .

HY-15780A

Brexpiprazole hydrochloride OPC-34712 hydrochloride	5-HT Receptor Dopamine Receptor Adrenergic Receptor	Neurological Disease
Brexpiprazole (OPC-34712) hydrochloride, an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D_2L receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole hydrochloride is also a 5-HT2A receptor antagonist with a K_i of 0.47 nM. Brexpiprazole hydrochloride also shows potent antagonist activity at human noradrenergic α_1B (K_i=0.17 nM) and α_2C receptors (K_i=0.59 nM) .

HY-U00194

Vebufloxacin Flumenique; OPC7241; DM8966	Bacterial	Infection
Vebufloxacin (Flumenique; OPC7241; DM8966) exhibits potent antibacterial activity against gram-positive and -negative bacteria.

HY-18346S

Mozavaptan-d6 OPC-31260-d₆	Isotope-Labeled Compounds Vasopressin Receptor	Metabolic Disease Endocrinology Cancer
Mozavaptan-d6 (OPC-31260-d6) is the deuterium labeled Mozavaptan. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V₂ receptor antagonist with an IC₅₀ of 14 nM. Mozavaptan shows ~85-fold selectivity for V₂ receptor over V₁ receptor (IC₅₀ of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .

HY-100665R

Dehydroaripiprazole (Standard) OPC-14857 (Standard); DM-14857 (Standard)	5-HT Receptor	Neurological Disease
Dehydroaripiprazole (Standard) is the analytical standard of Dehydroaripiprazole. This product is intended for research and analytical applications. Dehydroaripiprazole (OPC-14857) is an active metabolite of Aripiprazole. Aripiprazole is an antipsychotic agent and is metabolized by CYP3A4 and CYP2D6 forming mainly Dehydroaripiprazole. Dehydroaripiprazole has with antipsychotic activity equivalent to Aripiprazole .

HY-14546R

Aripiprazole (Standard) OPC-14597 (Standard)	5-HT Receptor Dopamine Receptor	Infection Neurological Disease Inflammation/Immunology
Aripiprazole (Standard) is the analytical standard of Aripiprazole. This product is intended for research and analytical applications. Aripiprazole (OPC-14597), an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole can be used for the research of schizophrenia and COVID19 .

HY-15780S

Brexpiprazole-d8 OPC-34712-d₈	5-HT Receptor Dopamine Receptor	Neurological Disease
Brexpiprazole-d₈ is a deuterium labeled Brexpiprazole (OPC-34712). Brexpiprazole, an atypical antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine receptor (Ki=0.12 nM and 0.3 nM, respectively). Brexpiprazole is also a 5-HT2A receptor antagonist (Ki=0.47 nM)[1][2].

HY-135910S

3,4-Dehydro Cilostazol-d11 OPC-13015-d₁₁	Drug Metabolite Isotope-Labeled Compounds	Cancer
3,4-Dehydro Cilostazol-d₁₁ is deuterated labeled 3,4-Dehydro Cilostazol (HY-135910). 3,4-Dehydro Cilostazol (OPC-13015) is an active metabolite of Cilostazol (CLZ; HY-17464). 3,4-Dehydro Cilostazol is used for pharmacokinetic study .

HY-B0360

Rebamipide 3 Publications Verification OPC12759; Proamipide	COX	Inflammation/Immunology Cancer
Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer .

HY-100665S

Dehydroaripiprazole-d8 OPC-14857-d₈; DM-14857-d₈	Isotope-Labeled Compounds 5-HT Receptor	Neurological Disease
Dehydroaripiprazole-d₈ is deuterium labeled Dehydroaripiprazole. Dehydroaripiprazole (OPC-14857) is an active metabolite of Aripiprazole. Aripiprazole is an antipsychotic agent and is metabolized by CYP3A4 and CYP2D6 forming mainly Dehydroaripiprazole. Dehydroaripiprazole has with antipsychotic activity equivalent to Aripiprazole[1][2][3].

HY-17464S1

Cilostazol-d4 OPC-13013-d₄	Isotope-Labeled Compounds Phosphodiesterase (PDE) Autophagy	Cardiovascular Disease Cancer
Cilostazol-d₄ is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].

HY-15780S1

Brexpiprazole-d8-1 OPC-34712-d₈-1	Dopamine Receptor Adrenergic Receptor 5-HT Receptor	Neurological Disease
Brexpiprazole-d₈-1 is the deuterium labeled Brexpiprazole[1]. Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[2][3].

HY-129041

Procaterol hydrochloride hemihydrate 1 Publications Verification OPC 2009 hydrochloride hemihydrate	Adrenergic Receptor	Infection Inflammation/Immunology
Procaterol hydrochloride hemihydrate is an orally active β2 adrenoreceptor agonist. Procaterol hydrochloride hemihydrate can be used for the research of asthma .

HY-17000

Tolvaptan Maximum Cited Publications 10 Publications Verification OPC-41061	Vasopressin Receptor Autophagy	Cardiovascular Disease Endocrinology Cancer
Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V₂R) antagonist with an IC₅₀ of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation. Tolvaptan induces cell apoposis and affects cell cycle. Tolvaptan can be used for the research of hyponatremia .

HY-10846

Delamanid 5 Publications Verification OPC-67683	Bacterial Antibiotic	Cancer
Delamanid, a newer mycobacterial cell wall synthesis inhibitor, inhibits the synthesisi of mucolic acids .

HY-101312

Cilostamide 2 Publications Verification OPC3689	Phosphodiesterase (PDE)	Cardiovascular Disease
Cilostamide is a selective and potent PDE3 inhibitor, with IC₅₀s of 27 nM and 50 nM for PDE3A and PDE3B, respectively, and has antithrombotic and anti-intimal hyperplastic activity.

HY-17495

Carteolol OPC-1085	Adrenergic Receptor Caspase Bcl-2 Family	Neurological Disease
Carteolol is a non-selective β-adrenoceptor antagonist. Carteolol induces apoptosis via a caspase activated and mitochondrial-dependent pathway. Carteolol can be used for glaucoma research .

HY-U00186

K134 OPC33509	Phosphodiesterase (PDE)	Cardiovascular Disease
K134 is a phosphodiesterase 3 (PDE3) inhibitor. The IC₅₀s of K134 toward PDE3A, PDE3B, PDE5, PDE2 and PDE4 are 0.1, 0.28, 12.1, >300 and >300 µM, respectively.

HY-10846S

Delamanid-d4 OPC-67683-d₄	Bacterial	Infection
Delamanid-d₄ is the deuterium labeled Delamanid. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, inhibits the synthesisi of mucolic acids[1].

HY-14546S

Aripiprazole-d8 OPC-14597-d₈	5-HT Receptor	Neurological Disease
Aripiprazole-d₈ is the deuterium labeled Aripiprazole, which is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM.

HY-10846S1

Delamanid-d4-1 OPC-67683-d₄-1	Isotope-Labeled Compounds	Cancer
Delamanid-d₄-1 is deuterated labeled Delamanid.Delamanid, a newer mycobacterial cell wall synthesis inhibitor, inhibits the synthesisi of mucolic acids .

HY-B0360S

Rebamipide-d4 OPC12759-d₄; Proamipide-d₄	COX Prostaglandin Receptor	Inflammation/Immunology Cancer
Rebamipide-d₄ is deuterium labeled Rebamipide. Rebamipide is a mucoprotective agent. Rebamipide induces COX-2 expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner[1].

HY-116567A

*(S)-OPC-51803*	Others	Endocrinology
(S)-OPC-51803 is an agonist of the vasopressin V2 receptor, with activity in suppressing nocturia and urinary incontinence. (S)-OPC-51803 was evaluated in terms of biological activity and showed a stronger V2 receptor agonist effect compared to its (R)-isomer. The use of (S)-OPC-51803 may improve the patient's ability to control nocturnal polyuria .

HY-117488

(S)-Grepafloxacin (S)-OPC-17116; (S)-dl-Grepafloxacin	Others	Infection
(S)-Grepafloxacin ((S)-OPC-17116) is the S-enantiomer of Grepafloxacin (HY-A0147) .

HY-P5982

PTPσ Inhibitor, ISP	Phosphatase	Neurological Disease
PTPσ Inhibitor, ISP can bind to recombinant human PTPs and inhibits PTPσ signaling. PTPσ Inhibitor, ISP can penetrate the membrane and relieves the chondroitin sulfate proteoglycan (CSPG)-mediated axonal sprouting inhibition in spinal cord injury model. PTPσ Inhibitor, ISP enhances remyelination in LPC-induced demyelinated spinal cord. PTPσ Inhibitor, ISP also promotes oligodendrocyte progenitor cells (OPCs) migration, maturation, remyelination, and functional recovery in animal models of Multiple Sclerosis (MS) .

Cat. No.	Product Name	Type

HY-10254G

Mirdametinib (GMP) PD0325901 (GMP); PD325901 (GMP)	Fluorescent Dye
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor .

Cat. No.	Product Name	Type

HY-10254G

Mirdametinib (GMP) PD0325901 (GMP); PD325901 (GMP)	Biochemical Assay Reagents
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor .

Cat. No.	Product Name	Target	Research Area

HY-P5982

PTPσ Inhibitor, ISP	Phosphatase	Neurological Disease
PTPσ Inhibitor, ISP can bind to recombinant human PTPs and inhibits PTPσ signaling. PTPσ Inhibitor, ISP can penetrate the membrane and relieves the chondroitin sulfate proteoglycan (CSPG)-mediated axonal sprouting inhibition in spinal cord injury model. PTPσ Inhibitor, ISP enhances remyelination in LPC-induced demyelinated spinal cord. PTPσ Inhibitor, ISP also promotes oligodendrocyte progenitor cells (OPCs) migration, maturation, remyelination, and functional recovery in animal models of Multiple Sclerosis (MS) .

HY-126785

Suc-AAP-Abu-pNA Colorimetric Elastase Substrate	Elastase	Others
Suc-AAP-Abu-pNA (Colorimetric Elastase Substrate) is a specific substrate for pancreatic elastase (K_m = 100 μM; K_cat/K_m = 35,300 s ^-1 M ^-1 for rat pancreatic elastase; K_m = 30 μM; K_cat/K_m = 351,000 s ^-1 M ^-1 for porcine pancreatic elastase). Suc-AAP-Abu-pNA also promotes OPC migration .

Cat. No.	Product Name	Chemical Structure

HY-15780S

Brexpiprazole-d8
Brexpiprazole-d₈ is a deuterium labeled Brexpiprazole (OPC-34712). Brexpiprazole, an atypical antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine receptor (Ki=0.12 nM and 0.3 nM, respectively). Brexpiprazole is also a 5-HT2A receptor antagonist (Ki=0.47 nM)[1][2].

HY-15780S1

Brexpiprazole-d8-1

Brexpiprazole-d₈-1 is the deuterium labeled Brexpiprazole[1]. Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[2][3].

HY-10846S

Delamanid-d4
Delamanid-d₄ is the deuterium labeled Delamanid. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, inhibits the synthesisi of mucolic acids[1].

HY-14546S

Aripiprazole-d8
Aripiprazole-d₈ is the deuterium labeled Aripiprazole, which is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM.

HY-17495AS

Carteolol-d9 hydrochloride
Carteolol-d₉ (hydrochloride) is the deuterium labeled Carteolol hydrochloride. Carteolol hydrochloride (OPC-1085 hydrochloride) is a non-selective beta blocker used to treat glaucoma[1][2].

HY-18346S

Mozavaptan-d6

Mozavaptan-d6 (OPC-31260-d6) is the deuterium labeled Mozavaptan. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V₂ receptor antagonist with an IC₅₀ of 14 nM. Mozavaptan shows ~85-fold selectivity for V₂ receptor over V₁ receptor (IC₅₀ of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .

HY-135910S

3,4-Dehydro Cilostazol-d11
3,4-Dehydro Cilostazol-d₁₁ is deuterated labeled 3,4-Dehydro Cilostazol (HY-135910). 3,4-Dehydro Cilostazol (OPC-13015) is an active metabolite of Cilostazol (CLZ; HY-17464). 3,4-Dehydro Cilostazol is used for pharmacokinetic study .

HY-100665S

Dehydroaripiprazole-d8
Dehydroaripiprazole-d₈ is deuterium labeled Dehydroaripiprazole. Dehydroaripiprazole (OPC-14857) is an active metabolite of Aripiprazole. Aripiprazole is an antipsychotic agent and is metabolized by CYP3A4 and CYP2D6 forming mainly Dehydroaripiprazole. Dehydroaripiprazole has with antipsychotic activity equivalent to Aripiprazole[1][2][3].

HY-17464S1

Cilostazol-d4
Cilostazol-d₄ is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].

HY-10846S1

Delamanid-d4-1
Delamanid-d₄-1 is deuterated labeled Delamanid.Delamanid, a newer mycobacterial cell wall synthesis inhibitor, inhibits the synthesisi of mucolic acids .

HY-B0360S

Rebamipide-d4
Rebamipide-d₄ is deuterium labeled Rebamipide. Rebamipide is a mucoprotective agent. Rebamipide induces COX-2 expression, increases PGE2 levels, and enhances gastric mucosal defense in a COX-2-dependent manner[1].

HY-14546S1

Aripiprazole (1,1,2,2,3,3,4,4-d8) 5+ Cited Publications
Aripiprazole (1,1,2,2,3,3,4,4-d₈) is the deuterium labeled Aripiprazole. Aripiprazole (OPC-14597) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM[1][2].

HY-17464S

Cilostazol-d11
Cilostazol-d₁₁ is the deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: